Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Opentrons Flex flexes the power of AI in lab automation

By Brian Buntz | May 29, 2023

Opentrons Flex

Opentrons Flex [Image courtesy of Opentrons]

Brooklyn-based lab automation company Opentrons has debuted its new Flex robot, with the aim of broadening access to advanced lab automation for life scientists. In a recent email interview, Opentrons CEO, Jonathan Brennan-Badal, highlighted that the Opentrons Flex robot is designed to offer a technically sophisticated, yet economically accessible automation platform for life scientists. The robot is designed to execute a variety of experiments, including those designed by large language models (LLMs) such as ChatGPT, he noted.

AI-generated automated protocols for life sciences

“Without wanting to be hyperbolic, LLMs will revolutionize how we design automated protocols in the life sciences,” Brennan-Badal explained. Opentrons’ compatibility with LLMs makes it possible to create “AI-generated automated protocols for every well-documented manual experiment in the scientific literature, as well as every commercially available molecular biology kit,” Brennan-Badal added. This capability, he believes, will greatly influence the pace and magnitude of biological experiments.

Currently, the development and refinement of a single nucleic acid extraction protocol can take a significant amount of time, ranging from weeks to months, as researchers strive to optimize variables such as sample type, DNA yield and quality and reproducibility. “That process could be vastly improved using AI,” Brennan-Badal said.

Flex designed to support affordable and efficient lab automation

In addition to its AI focus, Opentrons strives to carve out a nice for itself in a crowded lab automation space with notable players such as Labcyte, Tecan and Thermo Fisher Scientific by emphasizing affordability and efficiency. “Regarding the overall expenditure, the Flex’s cost is about a tenth of what its market counterparts demand,” according to Brennan-Badal. He credits this cost reduction to the company’s use of vertical integration in manufacturing processes and supply chain management.

The Flex robot is designed to be set up within a day, Brennan-Badal said. The system can be reconfigured by swapping out pipettes and hardware modules in a short amount of time. He attributes this modularity to the product design, on-device display instructions and smart sensors supporting auto-calibration.

The company also designed the Flex to have the capacity to learn. Brennan-Badal explains that the robot’s open application programming interface (API) is compatible with “design-of-experiment” programs, including AI-driven agents to support future developments in AI integration.

“For software, we have a no-code protocol designer GUI, an open repository of verified and community-submitted protocols available for download, as well as a well-documented Python API for those that want ultimate control over their protocol, or to integrate third-party devices or software with the robot,” Brennan-Badal said.

AI in lab automation: Enhancing flexibility and experiment design

One of the factors stoking interest in generative AI platforms are their ability to code in a variety of languages. Flex takes advantage of this capacity, Brennan-Badal noted. “We have demonstrated that LLMs including ChatGPT 3.5 and 4 can write, and correct, executable Python code to automate experiments such as serial dilutions and aliquoting on Opentrons robots, and we’re beginning to get good data for more complex protocols,” he said.

Researchers at Carnegie Mellon led by Gabe Gomes created an AI agent that combined LLMs to design chemical synthesis experiments, and then used these experimental designs as input to generate Python code to successfully automate the reactions on an Opentrons robot,” Brennan-Badal noted. That research was highlighted in the preprint “Emergent autonomous scientific research capabilities of large language models.”

Opentrons’ open and well-documented API is compatible with such programs. “LLMs can be trained on the large corpus of Opentrons’ automation and protocol data to generate new automated experimental protocols,” Brennan-Badal asserted. He noted that this capability makes its platforms future-facing in terms of their ability to work within AI frameworks.

An open source philosophy

Open-source technology is a core element of the Flex robot’s design, which could have implications for the scientific community. According to Brennan-Badal, the open-source approach can support scientists by enabling platform development and integration, and by fostering the sharing of protocols and knowledge.

The Flex robot’s open-source ethos offers significant implications for the scientific community. Brennan-Badal opined, “Being open source supports scientists in two fundamental ways. It liberates scientists to do new things, including building on the platform and integrating with other hardware and software. And it facilitates sharing of protocols and knowledge, allowing scientists around the world to reproduce each other’s work.”

Brennan-Badal also highlighted the role Opentrons played during the early days of the pandemic, noting how its automation capacity streamlined laboratory workflows. He highlighted the use of the OT-2 model in Opentrons’ own Pandemic Response Lab in New York City, where it contributed to COVID sample processing.

Future of life sciences with AI and Lab automation

Looking ahead, the integration of artificial intelligence, specifically large language models (LLMs), with lab automation could have implications for the future of life sciences. Brennan-Badal suggests that the combination of Opentrons’ compatibility with LLMs and the development of AI-generated automated protocols may influence the way biological experiments are conducted in terms of speed and scale.


Filed Under: Cell & gene therapy, Data science, Industry 4.0, machine learning and AI, Omics/sequencing
Tagged With: lab automation, large language models, life sciences, open-source technology, Opentrons Flex
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

How Thermo Fisher’s KingFisher PlasmidPro crunches hours of plasmid prep to 5 minutes hands-on
Can space help heal hearts? ISS study charts new path for stem cell therapy
MIT team designs gene circuits for tighter control in gene therapy study
Meet STITCHR, the retrotransposon-based gene editor that enables large, scarless DNA insertions
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE